Who
Andrew D. Dickinson
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Gilead Sciences; Former VP, Gen. Counsel & Sec, Myogen.
In numbers
- Trades disclosed
- 244
- Buys
- 0
- Sells
- 30
- Bought
- $0
- Sold
- $66.4M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 31 Jan 2006
- Last trade
- 15 Oct 2026
- Last filed
- 16 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 16 Oct 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $469K3,000 at $156.22 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $436K3,000 at $145.29 | filing |
| 15 Sep 2026filed 16 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $436K3,000 at $145.29 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $195K1,347 at $144.81 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,797 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $195K1,347 at $144.81 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $415K3,000 at $138.36 | filing |
| 17 Aug 2026filed 18 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $415K3,000 at $138.36 | filing |
| 15 Jul 2026filed 16 Jul 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $390K3,000 at $129.93 | filing |
| 15 Jul 2026filed 16 Jul 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $390K3,000 at $129.93 | filing |
| 15 Jun 2026filed 16 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $376K3,000 at $125.40 | filing |
| 15 Jun 2026filed 16 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $376K3,000 at $125.40 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,796 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $163K1,341 at $121.48 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,796 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,796 | filing |
| 10 Jun 2026filed 11 Jun 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —2,796 | filing |
News
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?GILD · aol.com · 25 Oct 20267,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A.GILD · dailypolitical.com · 24 Oct 2026Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026
0 headlines in the last 90 days name Andrew D. Dickinson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.